Adtralza

Tralokinumab is a fully human IgG4 monoclonal antibody that specifically binds interleukin-13 (IL-13), a type 2 cytokine, and blocks its interaction with IL-13 receptors.‍‍‍‍‍‍​​​‍​​​​​​ The drug neutralises the biological activity of IL-13 by inhibiting its binding to the IL-13Rα1/IL-4Rα receptor complex. Interleukin-13 plays a key role in the pathogenesis of atopic dermatitis — it promotes inflammation, impairs epidermal barrier function by affecting the expression of structural proteins (including filaggrin), and contributes to pruritus and chronic persistence of skin lesions. Inhibition of the IL-13 pathway by tralokinumab in patients leads to reduced activity of numerous inflammatory mediators, thereby alleviating the symptoms of atopic dermatitis. The bioavailability of tralokinumab after subcutaneous administration is approximately 60%. Tralokinumab is a protein and is therefore expected to be degraded into smaller peptides and subsequently into amino acids, which are utilised by the body as building blocks. The half-life of tralokinumab is approximately 22 hours.